Failure of a cytoprotective dose of Arbacet to heal acute gastric ulcers.
Twenty outpatients with an endoscopic diagnosis of gastric ulcer were evaluated for 6 wk in a randomized, double-blind trial comparing 15(R)-15-methyl prostaglandin E2 (Arbacet) (10 micrograms, 0.5 h before each meal and at bedtime) with placebo. Endoscopy was performed at 3 wk and 6 wk during the study period. Five of nine patients (56%) taking Arbacet and seven of 11 patients (64%) in the placebo group had complete healing of their gastric ulcer. Healing occurred in four patients from the Arbacet group and three patients in the placebo group at 3 wk. A cytoprotective dose of Arbacet (40 micrograms daily) is not significantly better than placebo in healing gastric ulcers.
Jaszewski
R
R
Department of Gastroenterology, Veterans Administration Medical Center/Wayne State University Affiliated Hospitals, Allen Park, Michigan.
Crane
S A
SA
D000208:Acute Disease; D001101:Arbaprostil / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005773:Gastroscopy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011459:Prostaglandins E, Synthetic / Q000627:therapeutic use*; D011897:Random Allocation; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
D010919:Placebos; D011459:Prostaglandins E, Synthetic; D001101:Arbaprostil